Tesis Biosciences on Friday announced a proposed study design to develop molecular biomarkers that differentiate mild traumatic brain injury (mTBI) from post-traumatic stress disorder (PTSD).
The firm said the study will apply a high-throughput genomics method to analyze peripheral blood mononuclear cells from veterans and civilians who were affected by mTBI and others who were not affected by the condition.
The study will identify changes in micro-RNA levels using a biomarker panel for mTBI, the company said, adding that the biomarkers could also monitor progress of short- and long-term therapies.
“By developing a molecular biomarker [for] mTBI that is highly accurate, relatively inexpensive, portable, and minimally invasive, we can improve outcome predictions and enable individualized treatments for our veterans and other Americans with mTBI,” Ron King, CEO of Tesis, said in a statement.
The firm is preparing an application for formal U.S. Food and Drug Administration (FDA) approval of the panel, Tesis added.
Its aim is to provide physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart disease, lung disease, and cancer through genetic testing.
